In vitro evaluation of the antitumor activity of axitinib in canine mammary gland tumor cell lines
Journal of Veterinary Science · 2024
DOI: 10.4142/jvs.23191 ↗At a glance
Journal article in Journal of Veterinary Science, 2024. Written by Hye-Gyu Lee and 5 co-authors. Institution: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seo…. Major MEDLINE topics: Vascular Endothelial Growth Factor A, Mammary Glands, Human. Cited 1 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Seoul National University.
Abstract (original language)
BACKGROUND: Axitinib, a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase 1,2 and 3, is used in chemotherapy because it inhibits tumor angiogenesis by blocking the VEGF/VEGFR pathway. In veterinary medicine, attempts have been made to apply tyrosine kinase inhibitors with anti-angiogenic effects to tumor patients, but there are no studies on axitinib in canine mammary gland tumors (MGTs). OBJECTIVES: This study aimed to confirm the antitumor activity of axitinib in canine mammary gland cell lines. METHODS: We treated canine MGT cell lines (CIPp and CIPm) with axitinib and conducted CCK, wound healing, apoptosis, and cell cycle assays. Additionally, we evaluated the expression levels of angiogenesis-associated factors, including VEGFs, PDGF-A, FGF-2, and TGF-β1, using quantitative real-time polymerase chain reaction. Furthermore, we collected canine peripheral blood mononuclear cells (PBMCs), activated them with concanavalin A (ConA) and lipopolysaccharide (LPS), and then treated them with axitinib to investigate changes in viability. RESULTS: When axitinib was administered to CIPp and CIPm, cell viability significantly decreased at 24, 48, and 72 h (p < 0.001), and migration was markedly reduced (6 h, p < 0.05; 12 h, p < 0.005). The apoptosis rate significantly increased (p < 0.01), and the G2/M phase ratio showed a significant increase (p < 0.001). Additionally, there was no significant change in the viability of canine PBMCs treated with LPS and ConA. CONCLUSION: In this study, we confirmed the antitumor activity of axitinib against canine MGT cell lines. Accordingly, we suggest that axitinib can be applied as a new treatment for patients with canine MGTs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.
- Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon 24341, Korea.
- Haemaru Referral Animal Hospital, Seongnam 13590, Korea.
- Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea. hyyoun@snu.ac.kr.
ORCID profiles: Hye-Gyu Lee, Ga-Hyun Lim, Ju-Hyun An, Su-Min Park, Kyoung-Won Seo, Hwa-Young Youn
Funding
- Seoul National University
Cite
APA
Lee, H. G., Lim, G. H., An, J. H., Park, S. M., Seo, K. W., & Youn, H. Y. (2024). In vitro evaluation of the antitumor activity of axitinib in canine mammary gland tumor cell lines. Journal of Veterinary Science. https://doi.org/10.4142/jvs.23191
Vancouver
Lee HG, Lim GH, An JH, Park SM, Seo KW, Youn HY. In vitro evaluation of the antitumor activity of axitinib in canine mammary gland tumor cell lines. Journal of Veterinary Science. 2024. doi:10.4142/jvs.23191
BibTeX
@article{Lee2024,
author = {Lee, Hye-Gyu and Lim, Ga-Hyun and An, Ju-Hyun and Park, Su-Min and Seo, Kyoung-Won and Youn, Hwa-Young},
title = {In vitro evaluation of the antitumor activity of axitinib in canine mammary gland tumor cell lines},
journal = {Journal of Veterinary Science},
year = {2024},
doi = {10.4142/jvs.23191}
}
EUVIMED